Fulcrum Occupancy–Leverage Perturbation Strategy Enables Rapid Discovery of Potent CDK2–Cyclin A2 Interaction Inhibitors

G Ge Sun (Pritzker School of Molecular Engineering) S Shuaishuai Chi (State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China) J Jiacheng Li (Department of Medicine, The University of Chicago, Chicago, IL, USA.) P Pan Xu T Tingting Lin C Chao Chen L Liping Liu Y Yulin Yang R Ruyu Yan (State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China) H Hongbo Han M Mingyu Wang S Shuiping Fu (State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China) J Junyi Qiu M Mingchen Wang F Fan Wei Y Yaxi Yang (State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China) J Jie Zheng (Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology) K Kaixian Chen (State Key Laboratory of Drug Research) S Shijie Chen (Innovation Center for AI and Drug Discovery, School of Pharmacy) Y Yi Chen B Bing Zhou C Cheng Luo (State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine)

Abstract

AbstractTraditional strategies for developing small‐molecule inhibitors of protein–protein interactions (PPIs) are time‐consuming and often yield low success rates due to the flat and dynamic interfaces of PPIs. To enable the rapid design of highly potent PPI inhibitors, we proposed a novel strategy named “Fulcrum Occupancy–Leverage Perturbation (FOLP)”. In this strategy, high‐affinity fragments serve as the “Fulcrum” by binding to the orthosteric pocket, while suitable moieties extend into allosteric sites near the PPI interface as “Leverage” to modulate the protein–protein interaction. As a proof of concept, the potent CDK2–Cyclin A2 PPI inhibitor LC‐K2CAin‐3, which fits the “FOLP” paradigm, was discovered with an IC50 of 32.1 nM for inhibiting the interaction. Molecular dynamics simulations and cryptic pocket identification were employed, revealing the activation loop (A‐loop) of CDK2 was flexible and targetable. X‐ray crystallography and hydrogen deuterium exchange mass spectrometry (HDX‐MS) analysis showed that LC‐K2CAin‐3 indeed bound to and stabilized the A‐loop. LC‐K2CAin‐3 effectively inhibited the CDK2–Cyclin A2 interaction in CDK2 highly expressed melanoma cells, leading to cell cycle arrest and apoptosis and inhibition of CDK2 mediated signaling. In conclusion, the “FOLP” strategy offers a novel approach for PPI inhibitor discovery and could accelerate the development of PPI inhibitors.

Article Details

Volume / Issue Vol. 64, Issue 41
Published October 06, 2025
ISSN 1433-7851
Publisher Wiley

Journal Info

Angewandte Chemie International Edition

Wiley

ISSN: 1433-7851 Physical Sciences

Authors (22)

G

Ge Sun

Pritzker School of Molecular Engineering

S

Shuaishuai Chi

State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China

J

Jiacheng Li

Department of Medicine, The University of Chicago, Chicago, IL, USA.

P

Pan Xu

T

Tingting Lin

C

Chao Chen

L

Liping Liu

Y

Yulin Yang

R

Ruyu Yan

State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China

H

Hongbo Han

M

Mingyu Wang

S

Shuiping Fu

State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China

J

Junyi Qiu

M

Mingchen Wang

F

Fan Wei

Y

Yaxi Yang

State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China

J

Jie Zheng

Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology

K

Kaixian Chen

State Key Laboratory of Drug Research

S

Shijie Chen

Innovation Center for AI and Drug Discovery, School of Pharmacy

Y

Yi Chen

B

Bing Zhou

C

Cheng Luo

State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine